ERBB2 and breast carcinoma: Everolimus: The BOLERO-2 trial, which was a randomized phase III trial, evaluated the combination of everolimus and exemestane in 724 postmenopausal women with ER-positive, HER2-negative advanced breast cancer considered refractory to anastrozole or letrozole.